RedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events

TEL AVIV, Israel and RALEIGH, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that RedHill’s Chief Executive Officer, Dror Ben-Asher, will present at the Morgan Stanley Annual Global Healthcare Conference, on Thursday, September 17, 2020.

Morgan Stanley Virtual 18^th Annual Global Healthcare Conference (Sept. 14-18)
Fireside chat and Q&A: Thursday, September 17, 2020
Time: 8:45 a.m. EDT
Speaker: Dror Ben-Asher, Chief Executive Officer

The Company will also present and hold one-on-one meetings at several additional events in September:

The Sixth Annual PharmaVOICE 100 Celebration
Bioforum Panel Presentation: Thursday, September 10, 2020
Topic: Developing Clinical Trial Outsourcing Strategies that Scale as Biotechs Do
Time: 12:10 a.m. EDT
Speaker: Guy Goldberg, Chief Business Officer

The Wall Street Investor Forum
Presentation: Thursday, September 10, 2020
Time: 11:40 a.m. EDT
Speaker: Dror Ben-Asher, Chief Executive Officer

H.C. Wainwright 22^nd Annual Healthcare Conference (Sept. 14-16)
Presentation and Q&A: Wednesday, September 16, 2020
Time: 10:00 a.m. EDT
Speaker: Guy Goldberg, Chief Business Officer

Healthtech Leaders Virtual Partnering & Investment Conference (Sept. 15-18)
Presentation: On-demand
Speaker: Guy Goldberg, Chief Business Officer

Sachs 20^th Annual Biotech in Europe Forum (Sept. 21-24)
Presentation: On-demand
Speaker: Guy Goldberg, Chief Business Officer

Panel: Virtual Therapeutic Strategies to Prevent & Treat COVID-19
Date: Monday, September 21, 2020
Time: 10:00 a.m. EDT/4:00 p.m. CET
Speaker: Gilead Raday, Chief Operating Officer 

All presentations will be broadcasted live and available via replay for 30 days on the Company's website: https://ir.redhillbio.com.

About RedHill Biopharma      
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs, Movantikfor opioid-induced constipation in adults¹, Talicia for the treatment of Helicobacter pylori (H. pylori) infection in adults², and Aemcolo for the treatment of travelers’ diarrhea in adults³. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-102 (Bekinda), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and is also being evaluated for COVID-19 and (vi) RHB-106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com.